MPC2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Mitoglitazone (SCHEMBL622605)	1.00	2/20
SCHEMBL623654	1.00	2/20
Mitoglitazone (SCHEMBL2221702)	0.98	2/20
Mitoglitazone (SCHEMBL2221427)	0.92	2/20
SCHEMBL6930322	0.82	2/20
SCHEMBL937521	0.80	2/20
SCHEMBL6928289	0.78	2/20
SCHEMBL935850	0.77	2/20
SCHEMBL937070	0.77	2/20
SCHEMBL624136	0.76	2/20
SCHEMBL624137	0.76	2/20
SCHEMBL626873	0.76	2/20
SCHEMBL935826	0.76	2/20
SCHEMBL625384	0.74	2/20
SCHEMBL625385	0.74	2/20
SCHEMBL6930536	0.73	2/20
Mitoglitazone (SCHEMBL2219522)	0.70	2/20
Mitoglitazone (SCHEMBL2224095)	0.70	2/20
SCHEMBL936346	0.69	2/20
SCHEMBL936979	0.67	2/20

Clinical trials — most relevant to MPC2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy	PHASE4	NOT_YET_RECRUITING
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.	PHASE4	COMPLETED
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:	PHASE3	ACTIVE_NOT_RECRUITING
Glutamate for Metabolic Intervention in Coronary Surgery	PHASE3	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)	PHASE2	RECRUITING
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis	PHASE2	RECRUITING
Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients	PHASE2	UNKNOWN
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA	PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate	EARLY_PHASE1	ENROLLING_BY_INVITATION
Hepatic Substrate Flux Rates in Type 2 Diabetes	nan	ACTIVE_NOT_RECRUITING
UTSW HP [13-C] Pyruvate Injection in HCM	nan	COMPLETED
Alternative Substrates in the Critically Ill Subject	nan	COMPLETED
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Neurometabolic Profile of Individuals With Primary Mitochondrial Disease	nan	RECRUITING
Mechanistic Study of PK2 Pathway in Alleviating Perioperative Neurocognitive Disorders by Improving Neurometabolic Uncoupling	nan	NOT_YET_RECRUITING
The Effect of White Tea Consumption on Obesity	nan	COMPLETED
In and ex Vivo Mitochondrial Function of the Heart	nan	COMPLETED
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus	nan	COMPLETED
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies	nan	RECRUITING
TBI Multimodal Monitoring Study	nan	UNKNOWN
KETO-TUMOR: a Study on Brain Tumors and Central Obesity	nan	RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Multi-Tracer Pet Quantitation of Insulin Action	nan	COMPLETED
Rhizomelic Chondrodysplasia Punctata Registry	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MPC2 binder may also engage these)

Protein	Name	Similarity
Q5R4Z3	—	1.000	Q5R4Z3 →
Q9D023	—	0.996	Q9D023 →
P38718	—	0.991	P38718 →
O49636	—	0.978	O49636 →
Q8L7H8	—	0.964	Q8L7H8 →
Q8LD38	—	0.947	Q8LD38 →
B2RZ37	—	0.942	B2RZ37 →
Q60870	—	0.939	Q60870 →
W5PFI3	—	0.938	W5PFI3 →
Q29RM3	—	0.936	Q29RM3 →
D3Z7Q2	—	0.935	D3Z7Q2 →
Q9CQ85	—	0.935	Q9CQ85 →
Q00765	—	0.934	Q00765 →
P11024	—	0.934	P11024 →
Q5RE33	—	0.933	Q5RE33 →
Q5U4U5	—	0.933	Q5U4U5 →
NNT	NAD(P) transhydrogenase, mitochondrial	0.933	landscape →
Q61941	—	0.932	Q61941 →
Q8N5G0	—	0.931	Q8N5G0 →
F1MDB2	—	0.931	F1MDB2 →
Q5BIN4	—	0.930	Q5BIN4 →
P00130	—	0.930	P00130 →
O60830	—	0.930	O60830 →
Q9JKW1	—	0.928	Q9JKW1 →
C0HLM6	—	0.928	C0HLM6 →
Q2HJE9	—	0.928	Q2HJE9 →
Q99KU0	—	0.928	Q99KU0 →
Q9Y584	—	0.927	Q9Y584 →
O35092	—	0.926	O35092 →
Q5M7K0	—	0.926	Q5M7K0 →